Association between Staphylococcus aureus nasal carriage and disease phenotype in patients affected by systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 18, Issue 1, 2016, Pages

  Conti, Fabrizio ^a   Ceccarelli, Fulvia ^a   Iaiani, Giancarlo ^b   Perricone, Carlo ^a   Giordano, Alessandra ^a   Amori, Luigino ^a   Miranda, Francesca ^a   Massaro, Laura ^a   Pacucci, Viviana Antonella ^a   Truglia, Simona ^a   Girelli, Gabriella ^b   Fakeri, Azis ^b   Taliani, Gloria ^a   Temperoni, Chiara ^a   Spinelli, Francesca Romana ^a   Alessandri, Cristiano ^a   Valesini, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

Author keywords

Microbiome; Staphylococcus aureus; Systemic lupus erythematosus

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY; AUTOANTIBODY;

ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CARRIER; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CLINICAL EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; KIDNEY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MICROBIOME; NONHUMAN; NOSE; NOSE SMEAR; PHENOTYPE; PHYSICAL EXAMINATION; STAPHYLOCOCCUS AUREUS; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; NOSE MUCOSA; PATHOLOGY;

ADULT; AUTOANTIBODIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NASAL MUCOSA; PHENOTYPE; STAPHYLOCOCCUS AUREUS;

EID: 84979771518     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-1079-x     Document Type: Article

References (36)

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110-21.
2. Rigante D, Esposito S. Infections and systemic lupus erythematosus: binding or sparring partners? Int J Mol Sci. 2015;16:17331-43.
3. McLean MH, Dieguez Jr D, Miller LM, Young HA. Does the microbiota play a role in the pathogenesis of autoimmune diseases? Gut. 2015;64:332-41.
4. Murillo N, Raoult D. Skin microbiota: overview and role in the skin diseases acne vulgaris and rosacea. Future Microbiol. 2013;8:209-22.
5. den Heijer CD, van Bijnen EM, Paget WJ, Pringle M, Goossens H, Bruggeman CA, APRES Study Team, et al. Prevalence and resistance of commensal Staphylococcus aureus, including meticillin-resistant S aureus, in nine European countries: a cross-sectional study. Lancet Infect Dis. 2013;13:409-15.
6. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005;5:751-62.
7. Mainous 3rd AG, Hueston WJ, Everett CJ, Diaz VA. Nasal carriage of Staphylococcus aureus and methicillin-resistant S aureus in the United States, 2001-2002. Ann Fam Med. 2006;4:132-7.
8. Tabarya D, Hoffman WL. Staphylococcus aureus nasal carriage in rheumatoid arthritis: antibody response to toxic shock syndrome toxin-1. Ann Rheum Dis. 1996;55:823-8.
9. Bassetti S, Wasmer S, Hasler P, Vogt T, Nogarth D, Frei R, et al. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. J Rheumatol. 2005;32:2125-9.
10. Tadema H, Heeringa P, Kallenberg CG. Bacterial infections in Wegener's granulomatosis: mechanisms potentially involved in autoimmune pathogenesis. Curr Opin Rheumatol. 2011;23:366-71.
11. Laudien M, Gadola SD, Podschun R, Hedderich J, Paulsen J, Reinhold-Keller E, et al. Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener s granulomatosis as compared to rheumatoid arthritis and chronic rhinosinusitis with nasal polyps. Clin Exp Rheumatol. 2010;28 Suppl 57:51-5.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
13. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7:1737-40.
14. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-91.
15. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992;10:541-7.
16. Conti F, Ceccarelli F, Perricone C, Miranda F, Truglia S, Massaro L, et al. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study. PLoS One. 2012;7:e45934.
17. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. J Rheumatol. 1992;19:1820-1.
18. Warnke P, Harnack T, Ottl P, Kundt G, Podbielski A. Nasal screening for Staphylococcus aureus-daily routine with improvement potentials. PLoS One. 2014;9:e89667.
19. Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis. 2003;37:933-8.
20. Sciascia S, Cuadrado MJ, Karim MY. Management of infection in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2013;27:377-89.
21. Crow MK. Type I, interferon in the pathogenesis of lupus. J Immunol. 2014;192:5459-68.
22. Conti F, Spinelli FR, Alessandri C, Valesini G. Toll-like receptors and lupus nephritis. Clin Rev Allergy Immunol. 2011;40:192-8.
23. Popa ER, Tervaert JW. The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions. Intern Med. 2003;42:771-80.
24. Ishizaki J, Saito K, Nawata M, Mizuno Y, Tokunaga M, Sawamukai N, et al. Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2015;54:405-12.
25. Spaan AN, Surewaard BG, Nijland R, van Strijp JA. Neutrophils versus Staphylococcus aureus: a biological tug of war. Annu Rev Microbiol. 2013;67:629-50.
26. Parker D, Prince A. Staphylococcus aureus induces type I IFN signaling in dendritic cells via TLR9. J Immunol. 2012;189:4040-6.
27. Parcina M, Wendt C, Goetz F, Zawatzky R, Zähringer U, Heeg K, et al. Staphylococcus aureus-induced plasmacytoid dendritic cell activation is based on an IgG-mediated memory response. J Immunol. 2008;181:3823-33.
28. Michea P, Vargas P, Donnadieu MH, Rosemblatt M, Bono MR, Duménil G, et al. Epithelial control of the human pDC response to extracellular bacteria. Eur J Immunol. 2013;43:1264-73.
29. Viau M, Zouali M. Effect of the B cell superantigen protein A from S. aureus on the early lupus disease of (NZBxNZW) F1 mice. Mol Immunol. 2005;42:849-55.
30. Goodyear CS, Silverman GJ. Staphylococcal toxin-induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. Proc Natl Acad Sci USA. 2004;101:11392-7.
31. Pauli NT, Kim HK, Falugi F, Huang M, Dulac J, Henry Dunand C, et al. Staphylococcus aureus infection induces protein A-mediated immune evasion in humans. J Exp Med. 2014;211:2331-9.
32. Ikeda T, Tamate N, Yamaguchi K, Makino S. Mass outbreak of food poisoning disease caused by small amounts of staphylococcal enterotoxins A and H. Appl Environ Microbiol. 2005;71:2793-5.
33. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev. 1999;20:435-59.
34. van den Akker EL, Nouwen JL, Melles DC, van Rossum EF, Koper JW, Uitterlinden AG, et al. Staphylococcus aureus nasal carriage is associated with glucocorticoid receptor gene polymorphisms. J Infect Dis. 2006;194:814-8.
35. Kao JS, Fluhr JW, Man MQ, Fowler AJ, Hachem JP, Crumrine D, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol. 2003;120:456-64.
36. Brown AF, Leech JM, Rogers TR, McLoughlin RM. Staphylococcus aureus colonization: modulation of host immune response and impact on human vaccine design. Front Immunol. 2014;4:507.